Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations

Documenti analoghi

• Agreement of Medication Information Derived From EHR Data Compared to Medicare Insurance Claims: An Analysis of Biologic Disease‐Modifying Antirheumatic Drugs
  di: Jing Li, et al.
  Pubblicazione: (2024)
• Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population‐Based Drug Utilisation Study
  di: Eleni Domzaridou, et al.
  Pubblicazione: (2025)
• COVID ‐19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database
  di: Mitsuhiro Mori, et al.
  Pubblicazione: (2026)
• Transportability Analyses in Comparative Effectiveness Research: A Conceptual Framework and Methodological Principles Endorsed by the I nternational S ociety for P harmacoepidemiology
  di: Blythe Adamson, et al.
  Pubblicazione: (2026)
• Impact of Regulatory Action on Dose Maximalization for Vitamin B6 Dietary Supplements on the Reporting Pattern for Neuropathy
  di: Florence van Hunsel, et al.
  Pubblicazione: (2025)